Penicillin allergy delabeling in long-term care facilities: if not now, then when?
Published
February 24, 2025
Source
Kap Sum Foong, Shira Doron, Alysse Wurcel
Antimicrob Steward Healthc Epidemiol.
2025 Feb 24;5(1):e61
PMID: 40026770
PMCID: PMC11869062
DOI: 10.1017/ash.2025.30
Abstract
Approximately 10% of the United States (US) population has a penicillin allergy label (PAL), yet studies show that up to 90% of these individuals are not truly allergic and can safely receive penicillin. This mislabeling contributes to negative health outcomes, including higher use of broad-spectrum antibiotics, increased healthcare costs, and greater risks of adverse effects such as Clostridioides difficile infection (CDI) and antimicrobial resistance.
Posted by
Levy CIMAR